/

Macro Radar Buy/Sell Trends Sector Rotation Portfolio Updates Institutions Guru Portfolios Insider Trades Smart Money Form 144 Pre-Sale 13D/13G Ownership 8-K Events Watchlist About Settings Login

/

Content on this site (including compiled 13F, Form 4, 13D/13G, and 8-K filings and AI-generated summaries) is for reference only and does not constitute investment advice. Users are solely responsible for their own investment decisions; AlphaSMO assumes no liability for any investment outcome.

ARWR

ARWR 13F Positioning & Ownership Changes

Arrowhead Pharmaceuticals In

-$192.0M

Net Activity

Institutions Holding

439

Popularity Rank

#1299

Avg Weight

0.19%

Total Value

$7.7B

Ownership Trend

439 institutions currently hold ARWR, with 262 net buyers and 180 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

180

Net Buying Institutions

262

Key Holders

Key Holders

Top 5 by Value

BlackRock, Inc.

Avoro Capital Advisors LLC

Vanguard Portfolio Management LLC

State Street CORP

Top 5 by Conviction

Western Financial Corp/CA

Avoro Capital Advisors LLC

Privium Fund Management B.V.

Vestal Point Capital, LP

View all 439 holding institutions

Quarterly Activity

Recent Activity

+$4.7B

Total Buy Value

$3.3B

Total Sell Value

New buy93

Trim119

Add169

Sold out61

262

Net Buyers

180

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding ARROWHEAD PHARMACEUTICALS IN (ARWR)?

Major stakeholders currently include BlackRock, Inc. ($1.1B), Avoro Capital Advisors LLC ($670.9M), FMR LLC ($455.6M). Based on the latest 13F filings, there are a total of 439 tracked investment funds and institutions maintaining positions in ARWR.

What is the overall institutional sentiment toward ARWR recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $192.0M, driven by 262 managers accumulating shares while 180 reduced their exposure.

Which institutions have been selling or reducing their ARWR positions?

In the latest period, 119 funds trimmed their holdings, and 61 managers completely exited their positions. The aggregate reported sell value was $3.3B.

Are there any notable investors adding ARWR to their portfolios?

Yes, buying activity remains notable. 93 institutions opened new positions in {ticker}, and 169 existing holders added to their shares. The total reported buy value for the quarter amounted to $4.7B.

Related Stocks

Same Sector

Other stocks in the same GICS sector

Johnson & Johnson

Institutions Holding

4,603

Total reported value

$438.8B

383 institutions currently hold both ARWR and this stock

Eli Lilly & Co

Institutions Holding

4,337

Total reported value

$730.5B

397 institutions currently hold both ARWR and this stock

Abbvie INC

Institutions Holding

4,024

Total reported value

$283.9B

383 institutions currently hold both ARWR and this stock

Trending Institutional Adds

The most-added stocks by 13F institutions this quarter

Microsoft CORP

Institutions Holding

6,150

Total reported value

$2.1T

3245 13F institutions increased their position this quarter

Amazon.com INC

Institutions Holding

5,957

Total reported value

$1.5T

3028 13F institutions increased their position this quarter

Nvidia CORP

Institutions Holding

5,764

Total reported value

$3.0T

2743 13F institutions increased their position this quarter